Scientists track Body's reaction to cancer immunotherapy
NCT ID NCT05707286
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 98 adults with cancers like melanoma and lung cancer who were starting immunotherapy. Researchers measured inflammatory markers in their blood to understand how the body reacts to these drugs. The goal was to find ways to better manage side effects from treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Can new drug cocktails reawaken the immune system against melanoma?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?